Therapy Detail

Therapy Name Doxorubicin + Cyclophosphamide
Therapy Description


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Cyclophosphamide Cytoxan CPM Chemotherapy - Alkylating 14 Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).
Doxorubicin Adriamycin Adria|ADR Chemotherapy - Anthracycline 11 TOPO2 inhibitor 4 Adriamycin (doxorubicin) is an anthracycline chemotherapeutic, in a non-liposomal formulation, which intercalates into DNA and inhibits topoisomerase II (PMID: 24367159). Doxorubicin is FDA approved for multiple cancer types (
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Clinical Trial Phase Therapies Title Recruitment Status
NCT01796197 Phase II Doxorubicin + Cyclophosphamide Pertuzumab + Trastuzumab Paclitaxel Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa Active, not recruiting
NCT02789657 Phase II Carboplatin + Pertuzumab + Trastuzumab + Paclitaxel Doxorubicin + Cyclophosphamide BrUOG 308: Efficacy of wPCbTP and Switching to an AC in Non-responding Patients as Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer. Recruiting
NCT03742986 Phase II Doxorubicin + Cyclophosphamide Nivolumab + Paclitaxel Docetaxel + Nivolumab + Pertuzumab + Trastuzumab Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC) Not yet recruiting
NCT01697293 Phase Ib/II Paclitaxel + Triciribine Doxorubicin + Cyclophosphamide Triciribine Phosphate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer Recruiting
NCT01501487 FDA approved Docetaxel + Doxorubicin + Cyclophosphamide Fluorouracil + Epirubicin + Cyclophosphamide Paclitaxel Pegfilgrastim Docetaxel + Cyclophosphamide Doxorubicin + Cyclophosphamide Trastuzumab + Docetaxel + Carboplatin Pertuzumab + Trastuzumab + Docetaxel MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I Completed
NCT02489448 Phase Ib/II MEDI4736 + nab-paclitaxel Doxorubicin + Cyclophosphamide Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer Active, not recruiting
NCT03036488 Phase III Epirubicin + Cyclophosphamide Doxorubicin + Cyclophosphamide Pembrolizumab Paclitaxel + Carboplatin Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) Active, not recruiting
NCT03726879 Phase III Doxorubicin + Cyclophosphamide Atezolizumab + Cyclophosphamide + Doxorubicin Atezolizumab + Paclitaxel + Trastuzumab + Pertuzumab Atezolizumab + Pertuzumab + Trastuzumab Pertuzumab + Trastuzumab Pertuzumab + Trastuzumab + Paclitaxel A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer (IMpassion050) Recruiting
NCT02032277 Phase III Doxorubicin + Cyclophosphamide Veliparib Carboplatin Paclitaxel + Carboplatin A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer Active, not recruiting
NCT01897441 Phase I Paclitaxel Trastuzumab + Paclitaxel Doxorubicin + Cyclophosphamide Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer Recruiting
NCT02876107 Phase II Doxorubicin + Cyclophosphamide Carboplatin + Paclitaxel + Panitumumab Paclitaxel + Carboplatin A Phase II Study of Using Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen (AC) for New Triple-Negative Inflammatory Breast Cancer (TN-IBC) Recruiting
NCT00574587 Phase Ib/II vorinostat + Paclitaxel Trastuzumab Doxorubicin + Cyclophosphamide Trial for Locally Advanced Her2 Positive Breast Cancer Using Paclitaxel, Trastuzumab, Doxorubicin and Cyclophasmide on a Weekly Basis Unknown status